Table 1

AxSpA outcome measures in relation to IBS status

No IBS symptoms* (n=127)IBS symptoms* (n=55)P value†
VAS global, mm30 (25)44 (25)0.010
VAS pain, mm30 (26)43 (26)0.020
VAS fatigue, mm32 (27)50 (27)0.001
EQ-5D utility‡0.75 (0.22)0.61 (0.30)0.004
BASDAI2.6 (2.1)4.3 (2.1)<0.001
BASFI1.8 (2.2)2.9 (2.2)0.016
BASMI3.1 (1.6)2.8 (1.4)0.609
Evaluator’s VAS global, mm16 (14)19 (14)0.569
  • Values are mean (SD). Missing data, n (%): VAS global/pain/fatigue 5 (3%), EQ-5D 12 (7%), BASDAI 12 (7%), BASFI 16 (9%), BASMI 4 (2%), Evaluator’s VAS global 11 (6%).

  • *Assessed by the ROME III questionnaire.

  • †Adjusted for sex and age by analysis of covariance.

  • ‡UK time trade-off based preference set.

  • AxSpA, axial spondyloarthritis; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; EQ-5D, EuroQol 5-Dimensions; IBS, irritable bowel syndrome; VAS, visual analogue scale.